Vertical Integration and Oncologists' Adoption of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
Integrated oncologists were quicker to adopt ICIs in the first year after FDA approval, but this lead was not sustained over time. Vertically integrating into health systems was not associated with significant changes in ICI use. Further research is needed on the factors influencing equitable dissemination of novel cancer therapies across practice settings.
Authors
- K. Robin Yabroff (ORCID: https://orcid.org/0000-0003-0644-5572)
- Xin Hu (ORCID: https://orcid.org/0000-0003-1097-3300)
- Changchuan Jiang (ORCID: https://orcid.org/0000-0002-7392-4154)
- Ilana Graetz (ORCID: https://orcid.org/0000-0003-3664-5815)
- Joseph Lipscomb
Institutions
- American Cancer Society (US)
- Emory University (US)
- Winship Cancer Institute
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Health Services Research
- Published
- 2025-02-19
- DOI
- https://doi.org/10.1111/1475-6773.14436
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pharmaceutical Research and Manufacturers of America Foundation
- California Department of Public Health
- University of Southern California
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute